Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of results from three clinical trials of VELCADE based therapies that showed consistently high complete remission(1) (CR) rates in patients with newly diagnosed multiple myeloma (MM). CR is one of the best predictors of long-term survival. These three studies were selected for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 30 - June 3, 2008. Highlights included:

-- VELCADE, cyclophosphamide, and dexamethasone (CyBorD) demonstrated a

CR rate of 46 percent prior to transplant and 72 percent

post-transplant

-- VELCADE, DOXIL and dexamethasone (PAD or VcDD) prior to transplant

showed a CR rate of 21 percent which increased to 59 percent

post-transplant

-- VELCADE, lenalidomide and dexamethasone (VRD) showed a CR rate of 35

percent at maximum planned dose and a 100 percent overall response

rate.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The goal of first-line therapy is to rapidly achieve the deepest and most durable response possible," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "VELCADE based combinations produce among the highest CR rates that are similar to those achieved by high dose therapy and transplantation. These very strong results underscore the critical role of VELCADE in patients with newly diagnosed multiple myeloma."

Efficacy of Induction with CyBorD in Newly Diagnosed Multiple Myeloma (Abstract #8517)

This study of CyBorD was designed to determine response in patients with newly diagnosed multiple myeloma. The results showed the status of 28 evaluable patients, who received cyclophosphamide at 300 mg/m2 on days 1, 8, 15, 22, VELCADE at 1
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Data Reviewed in End of Phase 2a Meeting , ... (Nasdaq: VIAP ), a biotechnology company focused on ... metabolic disease, announced today that an end of Phase 2a ... held with the U.S. Food and Drug Administration (FDA). ...
... New Capabilities Will Further Extend GeneXpert System Technology Advantages , ... CPHD ) today announced that it has received a ... and Infectious Diseases to develop new ten-color detection technology for ... be awarded to Cepheid and the University of Medicine ...
Cached Medicine Technology:VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 2Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 3Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 4
(Date:8/31/2014)... Aliso Viejo, California (PRWEB) August 31, 2014 ... release of ProPixie 5K. This plugin is a composite footage ... Cut Pro X. , “Adding particle footage to a video ... Christina Austin, CEO of Pixel Film Studios. “ProPixie 5K gives ... Editors can give their film an epic or magical ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 With the ... Conflict Institute hosted an interview with Yale University ... as well as Yale’s approach to ensuring student-athlete experience ... the interview, Conn highlighted a number of key factors ... university. A critical factor in creating this culture ...
(Date:8/31/2014)... 31 August 2014: Mortality and morbidity of atrial ... good use of oral anticoagulants, according to the one ... Registry. The findings were presented for the first time ... Gregory Lip (Birmingham, UK). , Professor Lip said: "This ... management practices of European cardiologists conducted since the ESC ...
(Date:8/30/2014)... Florida (PRWEB) August 31, 2014 Walking-Canes.Net ... walking and how a mobility device can help in making ... available for free download from the website that contains all ... doctor for this site. , The articles deal with diseases ... device like a walking cane can help in making life ...
(Date:8/30/2014)... August 31, 2014 This Labor Day, ... growing union in New York State and nationwide, is ... jobs and the best quality of care to New ... recent years, thousands of healthcare workers in the region ... families by becoming members of the healthcare workers’ union. ...
Breaking Medicine News(10 mins):Health News:Announcing a New ProPixie 5K Composite Footage Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 3Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Information Articles on Gait Problems from Walking-Canes.Net 2Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 2Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 3Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 4
... ... ... , ... , , ...
... ... use of mobile technology and their participation in online physician networking. Approximately 30% ... popular handheld device or smartphone is the Apple iPhone, with 31% of respondents owning ... Plymouth ...
... trouble by mid-40s, despite activity levels, study finds , WEDNESDAY, March ... 20s and 30s are more apt to develop heart disease risk ... spent less time in front of the screen, a new study ... news is that you can,t exercise the risk away. , The ...
... ... ... , , , ... ...
... ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:Statement from Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, On the Therapy Cap Coalition Press Conference 2Health News:SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone 2Health News:SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone 3Health News:You Can't Exercise Away TV's Toll on the Heart 2Health News:You Can't Exercise Away TV's Toll on the Heart 3Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 2Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 3Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 4Health News:Kaiser Permanente Completes Electronic Health Record Implementation 2Health News:Kaiser Permanente Completes Electronic Health Record Implementation 3Health News:Kaiser Permanente Completes Electronic Health Record Implementation 4Health News:Kaiser Permanente Completes Electronic Health Record Implementation 5Health News:Kaiser Permanente Completes Electronic Health Record Implementation 6Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 2Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 3Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 4
This compression garment can be used following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction,Lipectomy, Stomach Liposuction, Liposculpture, TummyTuck....
Select Support Brief...
Female High Waist Briefs...
Arm Compression Garment...
Medicine Products: